334 related articles for article (PubMed ID: 33168755)
21. The Broad Neutralizing Antibody Responses after HIV-1 Superinfection Are Not Dominated by Antibodies Directed to Epitopes Common in Single Infection.
Cortez V; Wang B; Dingens A; Chen MM; Ronen K; Georgiev IS; McClelland RS; Overbaugh J
PLoS Pathog; 2015 Jul; 11(7):e1004973. PubMed ID: 26158467
[TBL] [Abstract][Full Text] [Related]
22. Mapping Polyclonal HIV-1 Antibody Responses via Next-Generation Neutralization Fingerprinting.
Doria-Rose NA; Altae-Tran HR; Roark RS; Schmidt SD; Sutton MS; Louder MK; Chuang GY; Bailer RT; Cortez V; Kong R; McKee K; O'Dell S; Wang F; Abdool Karim SS; Binley JM; Connors M; Haynes BF; Martin MA; Montefiori DC; Morris L; Overbaugh J; Kwong PD; Mascola JR; Georgiev IS
PLoS Pathog; 2017 Jan; 13(1):e1006148. PubMed ID: 28052137
[TBL] [Abstract][Full Text] [Related]
23. Immunogenic Display of Purified Chemically Cross-Linked HIV-1 Spikes.
Leaman DP; Lee JH; Ward AB; Zwick MB
J Virol; 2015 Jul; 89(13):6725-45. PubMed ID: 25878116
[TBL] [Abstract][Full Text] [Related]
24. What Do Chaotrope-Based Avidity Assays for Antibodies to HIV-1 Envelope Glycoproteins Measure?
Alexander MR; Ringe R; Sanders RW; Voss JE; Moore JP; Klasse PJ
J Virol; 2015 Jun; 89(11):5981-95. PubMed ID: 25810537
[TBL] [Abstract][Full Text] [Related]
25. Evolution of cross-neutralizing antibody specificities to the CD4-BS and the carbohydrate cloak of the HIV Env in an HIV-1-infected subject.
Mikell I; Stamatatos L
PLoS One; 2012; 7(11):e49610. PubMed ID: 23152926
[TBL] [Abstract][Full Text] [Related]
26. Identification of Novel Structural Determinants in MW965 Env That Regulate the Neutralization Phenotype and Conformational Masking Potential of Primary HIV-1 Isolates.
Qualls ZM; Choudhary A; Honnen W; Prattipati R; Robinson JE; Pinter A
J Virol; 2018 Mar; 92(5):. PubMed ID: 29237828
[TBL] [Abstract][Full Text] [Related]
27. Polyfunctional Tier 2-Neutralizing Antibodies Cloned following HIV-1 Env Macaque Immunization Mirror Native Antibodies in a Human Donor.
Spencer DA; Malherbe DC; Vázquez Bernat N; Ádori M; Goldberg B; Dambrauskas N; Henderson H; Pandey S; Cheever T; Barnette P; Sutton WF; Ackerman ME; Kobie JJ; Sather DN; Karlsson Hedestam GB; Haigwood NL; Hessell AJ
J Immunol; 2021 Mar; 206(5):999-1012. PubMed ID: 33472907
[TBL] [Abstract][Full Text] [Related]
28. Induction of tier-2 neutralizing antibodies in mice with a DNA-encoded HIV envelope native like trimer.
Xu Z; Walker S; Wise MC; Chokkalingam N; Purwar M; Moore A; Tello-Ruiz E; Wu Y; Majumdar S; Konrath KM; Kulkarni A; Tursi NJ; Zaidi FI; Reuschel EL; Patel I; Obeirne A; Du J; Schultheis K; Gites L; Smith T; Mendoza J; Broderick KE; Humeau L; Pallesen J; Weiner DB; Kulp DW
Nat Commun; 2022 Feb; 13(1):695. PubMed ID: 35121758
[TBL] [Abstract][Full Text] [Related]
29. Cross-Linking of a CD4-Mimetic Miniprotein with HIV-1 Env gp140 Alters Kinetics and Specificities of Antibody Responses against HIV-1 Env in Macaques.
Shen X; Bogers WM; Yates NL; Ferrari G; Dey AK; Williams WT; Jaeger FH; Wiehe K; Sawant S; Alam SM; LaBranche CC; Montefiori DC; Martin L; Srivastava I; Heeney J; Barnett SW; Tomaras GD
J Virol; 2017 Oct; 91(19):. PubMed ID: 28490585
[TBL] [Abstract][Full Text] [Related]
30. Conformational antigenic heterogeneity as a cause of the persistent fraction in HIV-1 neutralization.
Colin P; Ringe RP; Yasmeen A; Ozorowski G; Ketas TJ; Lee WH; Ward AB; Moore JP; Klasse PJ
Retrovirology; 2023 May; 20(1):9. PubMed ID: 37244989
[TBL] [Abstract][Full Text] [Related]
31. Polyclonal antibody responses to HIV Env immunogens resolved using cryoEM.
Antanasijevic A; Sewall LM; Cottrell CA; Carnathan DG; Jimenez LE; Ngo JT; Silverman JB; Groschel B; Georgeson E; Bhiman J; Bastidas R; LaBranche C; Allen JD; Copps J; Perrett HR; Rantalainen K; Cannac F; Yang YR; de la Peña AT; Rocha RF; Berndsen ZT; Baker D; King NP; Sanders RW; Moore JP; Crotty S; Crispin M; Montefiori DC; Burton DR; Schief WR; Silvestri G; Ward AB
Nat Commun; 2021 Aug; 12(1):4817. PubMed ID: 34376662
[TBL] [Abstract][Full Text] [Related]
32. The C3/465 glycan hole cluster in BG505 HIV-1 envelope is the major neutralizing target involved in preventing mucosal SHIV infection.
Charles TP; Burton SL; Arunachalam PS; Cottrell CA; Sewall LM; Bollimpelli VS; Gangadhara S; Dey AK; Ward AB; Shaw GM; Hunter E; Amara RR; Pulendran B; van Gils MJ; Derdeyn CA
PLoS Pathog; 2021 Feb; 17(2):e1009257. PubMed ID: 33556148
[TBL] [Abstract][Full Text] [Related]
33. Complete functional mapping of infection- and vaccine-elicited antibodies against the fusion peptide of HIV.
Dingens AS; Acharya P; Haddox HK; Rawi R; Xu K; Chuang GY; Wei H; Zhang B; Mascola JR; Carragher B; Potter CS; Overbaugh J; Kwong PD; Bloom JD
PLoS Pathog; 2018 Jul; 14(7):e1007159. PubMed ID: 29975771
[TBL] [Abstract][Full Text] [Related]
34. Comparative Immunogenicity of Evolved V1V2-Deleted HIV-1 Envelope Glycoprotein Trimers.
Bontjer I; Melchers M; Tong T; van Montfort T; Eggink D; Montefiori D; Olson WC; Moore JP; Binley JM; Berkhout B; Sanders RW
PLoS One; 2013; 8(6):e67484. PubMed ID: 23840716
[TBL] [Abstract][Full Text] [Related]
35. Increased breadth of HIV-1 neutralization achieved by diverse antibody clones each with limited neutralization breadth.
Chukwuma VU; Kose N; Sather DN; Sapparapu G; Falk R; King H; Singh V; Lampley R; Malherbe DC; Ditto NT; Sullivan JT; Barnes T; Doranz BJ; Labranche CC; Montefiori DC; Kalams SA; Haigwood NL; Crowe JE
PLoS One; 2018; 13(12):e0209437. PubMed ID: 30566528
[TBL] [Abstract][Full Text] [Related]
36. Induction of Tier 1 HIV Neutralizing Antibodies by Envelope Trimers Incorporated into a Replication Competent Vesicular Stomatitis Virus Vector.
Bresk CA; Hofer T; Wilmschen S; Krismer M; Beierfuß A; Effantin G; Weissenhorn W; Hogan MJ; Jordan APO; Gelman RS; Montefiori DC; Liao HX; Schmitz JE; Haynes BF; von Laer D; Kimpel J
Viruses; 2019 Feb; 11(2):. PubMed ID: 30769947
[TBL] [Abstract][Full Text] [Related]
37. Rapid Induction of Multifunctional Antibodies in Rabbits and Macaques by Clade C HIV-1 CAP257 Envelopes Circulating During Epitope-Specific Neutralization Breadth Development.
Malherbe DC; Wibmer CK; Nonyane M; Reed J; Sather DN; Spencer DA; Schuman JT; Guo B; Pandey S; Robins H; Park B; Fuller DH; Sacha JB; Moore PL; Hessell AJ; Haigwood NL
Front Immunol; 2020; 11():984. PubMed ID: 32582155
[TBL] [Abstract][Full Text] [Related]
38. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
Jones AT; Chamcha V; Kesavardhana S; Shen X; Beaumont D; Das R; Wyatt LS; LaBranche CC; Stanfield-Oakley S; Ferrari G; Montefiori DC; Moss B; Tomaras GD; Varadarajan R; Amara RR
J Virol; 2018 Mar; 92(5):. PubMed ID: 29237847
[TBL] [Abstract][Full Text] [Related]
39. An HIV-1 Broadly Neutralizing Antibody from a Clade C-Infected Pediatric Elite Neutralizer Potently Neutralizes the Contemporaneous and Autologous Evolving Viruses.
Kumar S; Panda H; Makhdoomi MA; Mishra N; Safdari HA; Chawla H; Aggarwal H; Reddy ES; Lodha R; Kumar Kabra S; Chandele A; Dutta S; Luthra K
J Virol; 2019 Feb; 93(4):. PubMed ID: 30429339
[TBL] [Abstract][Full Text] [Related]
40. HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design.
Bricault CA; Yusim K; Seaman MS; Yoon H; Theiler J; Giorgi EE; Wagh K; Theiler M; Hraber P; Macke JP; Kreider EF; Learn GH; Hahn BH; Scheid JF; Kovacs JM; Shields JL; Lavine CL; Ghantous F; Rist M; Bayne MG; Neubauer GH; McMahan K; Peng H; Chéneau C; Jones JJ; Zeng J; Ochsenbauer C; Nkolola JP; Stephenson KE; Chen B; Gnanakaran S; Bonsignori M; Williams LD; Haynes BF; Doria-Rose N; Mascola JR; Montefiori DC; Barouch DH; Korber B
Cell Host Microbe; 2019 Jan; 25(1):59-72.e8. PubMed ID: 30629920
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
